MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition
L. Vande Walle, I. B. Stowe, P. Sacha, B. L. Lee, D. Demon, A. Fossoul, F. Van Hauwermeiren, P. H. V. Saavedra, P. Simon, V. Subrt, L. Kostka, C. E. Stivala, V. C. Pham, S. T. Staben, S. Yamazoe, , M. Lamkanfi
This study identifies the NACHT domain of wildtype NLRP3 as the target of MCC950/CRID3, showing it inhibits inflammasome activity but not CAPS-associated mutants.
bioRxiv · May 11, 2019Immunology